Delpor Awarded $220K NIH Grant for 3-month Exenatide Implant for the Treatment of Type 2 Diabetes
The NIDDK funds Delpor’s efforts to utilize its NANOPORTM technology in developing a matchstick-size subcutaneous implant device capable of delivering exenatide for 3-12 months through passive diffusion SAN FRANCISCO, CA, Oct [...]
Delpor Awarded $340K NIH Grant for 3-month Long Acting Risperidone Product in order to Improve Medication Adherence in Schizophrenia and Bipolar Disorder
Delpor’s innovative Prozor technology receives support from the National Institute of Mental Health in an effort to reduce relapse in patients suffering from schizophrenia and bipolar disorder. SAN FRANCISCO, CA, [...]
Ernest Mario Joins the Board of Delpor, Inc.
Delpor continues to strengthen its expertise in drug delivery with the addition of the former CEO of Glaxo and Alza to its Board of Directors. SAN FRANCISCO, CA, January 19, [...]
Delpor, Inc. Announces Scientific Advisory Board with Experts in Psychiatry and Drug Delivery
Panel of internationally renowned researchers and clinicians will guide development of Delpor’s drug delivery based products in schizophrenia, hepatitis C, diabetes, and other diseases. SAN FRANCISCO, CA, July 13, 2011 [...]
Delpor, Inc. Announces Issuance of Nanopore Drug Delivery Patent
Nanopore technology enables the sustained release of drugs during several months from a small subcutaneous implant device. SAN FRANCISCO, CA, June 23, 2011 – Delpor, Inc. (Delpor), a biotechnology company [...]